Deregulation of the TP53/p14ARF Tumor Suppressor Pathway in Low-Grade Diffuse Astrocytomas and Its Influence on Clinical Course

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4884-4890

  Watanabe, Takao ^a   Katayama, Yoichi ^a   Yoshino, Atsuo ^a   Komine, Chiaki ^a   Yokoyama, Takakazu ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P14ARF; PROTEIN P15; PROTEIN P16; CDK4 PROTEIN, HUMAN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INHIBITION; CANCER SURVIVAL; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; DEREGULATION; DISEASE COURSE; GENE DELETION; GENE MUTATION; GENE TARGETING; GLIOMA; HUMAN; HUMAN TISSUE; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; CODON; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; EXON; FEMALE; HOMOZYGOTE; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CODON; CPG ISLANDS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; DNA METHYLATION; EXONS; FEMALE; GENE DELETION; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0142250368     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kleihues, P., and Ohgaki, H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol., 7: 1131-1136, 1997.
2. Kleihues, P., and Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology, 1: 44-51, 1999.
3. Piepmeier, J., Christopher, S., Spencer, D., Byrne, T., Kim, J., Knisel, J. P., Lacy, J., Tsukerman, L., and Makuch, R. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery, 38: 872-879, 1996.
4. Watanabe, T., Katayama, Y., Yoshino, A., Komine, C., Yokoyama, T., and Fukushima, T. Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy. J. Neuro-Oncol., 61: 171-176, 2002.
5. Ishii, N., Tada, M., Hamou, M. F., Janzer, R. C., Meagher-Villemure, K., Wiestler, O. D., de Tribolet, N., and Van Meier, E. G. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene, 18: 5870-5878, 1999.
6. Peraud, A., Kreth, F. W., Wiestler, O. D., Kleihues, P., and Reulen, H. J. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin. Cancer Res., 8: 1117-1124, 2002.
7. Watanabe, K., Sato, K., Biernat, W., Tachibana, O., von Ammon, K., Ogata, N., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res., 3: 523-530, 1997.
8. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
9. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
10. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
11. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
12. Hannon, G. J., and Beach, D. p15INK4b is a potential effecter of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
13. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
14. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDK2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
15. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for a p15INK4B. Cancer Res., 56: 722-777, 1996.
16. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol., 11: 159-168, 2001.
17. INK4a genes in oligodendrogliomas. Acta Neuropathol., 101: 185-189, 2001.
18. Watanabe, T., Yokoo, H., Yokoo, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J. Neuropathol. Exp. Neurol., 60: 1181-1189, 2001.
19. Dong, S. M., Pang, C. S., Poon, W. A., Hu, J., To, K. F., Chang, A. R., and Ng, H. K. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol., 60: 808-816, 2001.
20. Wolter, M., Reifenberger, J., Blaschke, B., Ichimura, K., Schmidt, E. E., Collins, V. P., and Reifenberger, G. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J. Neuropathol. Exp. Neurol., 60: 1170-1180, 2001.
21. Kleihues, P., and Cavenee, W. K. (eds.), Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC, 2000.
22. Brüstle, O., Ohgaki, H., Schmitt, H. P., Walter, G. F., Ostertag, H., and Kleihues, P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: association with an activated K-ras gene. Cancer (Phila.), 69: 2385-2392, 1992.
23. Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
24. Nakamura, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab. Investig., 81: 77-82, 2001.
25. Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., and Ohgaki, H. Alteration of cell cycle regulatory gene in primary (de novo) and secondary glioblastomas. Acta Neuropathol., 94: 303-309, 1997.
26. Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol., 56: 180-185, 1997.
27. 1/S transition and their response to DNA damage. FEBS Lett., 490: 117-122, 2001.
28. 2/M transition by p53. Oncogene, 20: 1803-1815, 2001.
29. 1-S transition control gene abnormalities. Cancer Res., 60: 417-424, 2000.
30. Issa, J. P., Ahuja, N., Toyota, M., Bronner, M. P., and Brentnall, T. A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res., 61: 3573-3577, 2001.
31. Shen, L., Kondo, Y., Hamilton, S. R., Rashid, A., and Issa, J. P. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology, 124: 626-633, 2003.
32. INK4a methylation and p53 mutational status. Cancer Res., 60: 129-133, 2000.
33. Pinyol, M., Hernandez, L., Martinez, A., Cobo, F., Hernandez, S., Bea, S., Lopez-Guillermo, A., Nayach, I., Palacin, A., Nadal, A., Fernandez, P. L., Montserrat, E., Cardesa, A., and Campo, E. INK4a/ARF alterations in human non-Hodgkin's lymphoma mainly occur in tumors with wild-type p53 gene. Am. J. Pathol., 156: 1987-1996, 2000.
34. Tannapfel, A., Busse, C., Weinans, L., Benicke, M., Katalinic, A., Geißler, F., Hauss, J., and Wittekind, C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene, 20: 7104-7109, 2001.
35. Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., and Van Meir, E. G. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene, 19: 3816-3822, 2000.
36. Gazzeri, S., Della-Valle, V., Chaussade, L., Brambilla, C., Larsen, C. J., and Brambilla, E. The human p19ARF protein encoded by the β transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res., 58: 3926-3931, 1998.
37. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. Tumor spectrum in ARF-deficient mice. Cancer Res., 59: 2217-2222, 1999.
38. Esteller, M., González, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capella, G., and Peinado, M. A. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol., 19: 299-304, 2001.
39. Orlow, I., Drobnjak, M., Zhang, Z. F., Lewis, J., Woodruff, J. M., Bernnan, M. F., and Cordon-Cardo, C. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J. Natl. Cancer Inst. (Bethesda), 91: 73-79, 1999.
40. ARF in 105 human primary gliomas. Oncogene, 20: 1103-1109, 2001.
41. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Dev., 7: 546-554, 1993.
42. Morgenbesser, S. D., Williams, B. O., Jacks, T., and DePinho, R. A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (Lond.), 371: 72-74, 1994.
43. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
44. Keles, G. E., Lamborn, K. L., and Berger, M. S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J. Neurosurg., 95: 735-745, 2001.